564O_PR - Oncologists’ preferences for recommending expensive anticancer drugs

Date 19 December 2016
Event ESMO Asia 2016 Congress
Session Access to medicines: A global policy issue
Topics Anticancer agents
Bioethics, Legal, and Economic Issues
Presenter Deme Karikios
Citation Annals of Oncology (2016) 27 (suppl_9): ix184-ix189. 10.1093/annonc/mdw603
Authors D.J. Karikios1, K. Howard2, P. Blinman3, M.R. Stockler1
  • 1Nhmrc Clinical Trials Centre, University of Sydney, 1450 - Sydney/AU
  • 2Sydney School Of Public Health, University of Sydney, 2006 - Sydney/AU
  • 3Concord Cancer Centre, Concord Repatriation General Hospital, 2139 - Sydney/AU

Abstract

Background

Oncologists and patients are frequently faced with difficult treatment decisions about expensive anticancer drugs. The aim of this study was to understand how different attributes of anticancer drugs, including their out-of-pocket costs, influenced oncologists’ recommendations.

Methods

Members of the Medical Oncology Group of Australia were invited to complete a discrete choice experiment online. Respondents were presented with 15 choice sets describing two hypothetical anticancer drugs (A or B) and were asked to indicate which they preferred to recommend to a hypothetical patient with advanced cancer. Drug B was assigned an out-of-pocket cost in most choice sets, whereas drug A was always A$0 out-of-pocket. A mixed logit model was constructed to determine the effect of different attributes and respondent characteristics on recommendations. Trade-offs between out-of-pocket cost and survival were calculated.

Results

We received 101 evaluable responses. Most respondents were fully qualified (75%) and had predominantly public (65%), metropolitan (78%) practices. Respondents were more likely to recommend anticancer drugs with longer survival (OR = 2.16 per extra month, p 

Conclusions

Australian oncologists are willing to recommend expensive anticancer drugs to their patients, exposing them to financial toxicity. A better understanding of patient preferences for expensive anticancer drugs and how oncologists can help patients determine their value is required.

Clinical trial indentification

Legal entity responsible for the study

University of Sydney

Funding

University of Sydney

Disclosure

All authors have declared no conflicts of interest.